Cargando…

Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in cardiovascular outcome trials in type 2 diabetes mellitus. However, the most convincing evidence was obtained in subjects with established cardiovascular (CV) disease. We analyzed the determinants...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piccini, Sara, Favacchio, Giuseppe, Panico, Cristina, Morenghi, Emanuela, Folli, Franco, Mazziotti, Gherardo, Lania, Andrea Gerardo, Mirani, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039680/ https://www.ncbi.nlm.nih.gov/pubmed/36966321 http://dx.doi.org/10.1186/s12933-023-01800-z

Ejemplares similares

Weight change and glycemic control in type 2 diabetes patients during COVID-19 pandemic: the lockdown effect
por: Biamonte, Emilia, et al.
Publicado: (2021)

Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study
por: Pizzocaro, Alessandro, et al.
Publicado: (2021)

Biochemical Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors by Cardiovascular Risk Profile and Volume Status in a Real-World Diabetic Population
por: Gitto, Mauro, et al.
Publicado: (2022)

Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice
por: Mazziotti, Gherardo, et al.
Publicado: (2022)

COVID-19 ed endocrinologia: il caso della tiroide, del diabete e dell’ipovitaminosi D
por: Antonini, Simone, et al.
Publicado: (2021)

Comparative cardiovascular effects of GLP‐1 agonists using real‐world data
por: Wallia, Amisha, et al.
Publicado: (2023)

The benefit of statins in SARS-CoV-2 patients: further metabolic and prospective clinical studies are needed
por: Bifulco, Maurizio, et al.
Publicado: (2020)

MON-LB028 Comparing Cardiovascular Effects of GLP-1 Agonists in a Real World Setting
por: Wallia, Amisha, et al.
Publicado: (2019)

Vitamin D deficiency, secondary hyperparathyroidism and respiratory insufficiency in hospitalized patients with COVID-19
por: Mazziotti, G., et al.
Publicado: (2021)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism
por: Andreozzi, Francesco, et al.
Publicado: (2016)

Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges
por: Pugliese, Nicola, et al.
Publicado: (2022)

Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review
por: Panico, Cristina, et al.
Publicado: (2023)

The complementary role of PSMA expression and [(18)F]FDG PET/CT in predicting thyroid cancer outcome: from black and white to shades of gray, in the era of precision oncology
por: Sollini, Martina, et al.
Publicado: (2023)

An overview of GLP-1 agonists and recent cardiovascular outcomes trials
por: Sheahan, Kelsey H, et al.
Publicado: (2020)

Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study
por: Zhou, Yu, et al.
Publicado: (2022)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies
por: Li, Junfeng, et al.
Publicado: (2017)

AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus
por: Berra, Cesare, et al.
Publicado: (2023)

Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01)
por: Berra, Cesare C., et al.
Publicado: (2023)

Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment
por: Vitali, Eleonora, et al.
Publicado: (2020)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
por: del Olmo-Garcia, María Isabel, et al.
Publicado: (2018)

Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
por: Dadwani, Rahul S., et al.
Publicado: (2023)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Case Report: New CDKN1B Mutation in Multiple Endocrine Neoplasia Type 4 and Brief Literature Review on Clinical Management
por: Lavezzi, Elisabetta, et al.
Publicado: (2022)

Cardiovascular Benefits of GLP-1 Receptor Agonism: Is Inflammation a Key?
por: Marx, Nikolaus, et al.
Publicado: (2018)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS
por: Yang, Zheng, et al.
Publicado: (2022)

FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist
por: Fansa, Sima, et al.
Publicado: (2023)

Gestione clinica della terapia con Denosumab: in chi, quando e come interromperla
por: Pigni, Stella, et al.
Publicado: (2023)

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies
por: Caruso, Irene, et al.
Publicado: (2022)

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
por: Longato, Enrico, et al.
Publicado: (2020)

Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
por: Yang, Chen-Yi, et al.
Publicado: (2021)

Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes
por: Palanca, Ana, et al.
Publicado: (2023)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Clinical Trial Highlights – GLP-1 agonists
por: McFarthing, Kevin, et al.
Publicado: (2020)

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
por: Yang, Chun-Ting, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t7i2j7te1a4tmdsve4snt5l8i1